Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tengion Inc. (TNGNQ : OTC)
 
 • Company Description   
Tengion, Inc. is a clinical-stage biotechnology company, focused on discovering, developing, manufacturing and commercializing a range of replacement neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company creates these functional neo-organs and neo-tissues using a patient's autologous cells, in conjunction with its Organ Regeneration Platform. Tengion's lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The Company intends to develop our technology to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. Tengion, Inc. is headquartered in East Norriton, Pennsylvania.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.02 Daily Weekly Monthly
20 Day Moving Average: 0 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: -88.83
52 Week High: $0.02
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 12.64%
12 Week 0.00% 9.94%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3929 WESTPOINT BLVD. SUITE G
-
WINSTON-SALEM,NC 27103
USA
ph: 336-722-5855
fax: -
ir@tengion.com http://www.tengion.com
 
 • General Corporate Information   
Officers
David I. Scheer - Chairman
John L. Miclot - President and Chief Executive Officer
A. Brian Davis - Chief Financial Officer and Senior Vice President
Carl-Johan Dalsgaard - Director
Diane K. Jorkasky - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 88034G208
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 6.00 (0.10:1)
Beta: -88.83
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©